PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and 68Ga‐PSMA‐11 PET Using Cyclotron‐Produced 68Ga

Autor: Scott M. Thompson, Garima Suman, Michael S. Torbenson, Zong‐Ming E. Chen, Danielle E. Jondal, Anurima Patra, Eric C. Ehman, James C. Andrews, Chad J. Fleming, Brian T. Welch, Anil N. Kurup, Lewis R. Roberts, Kymberly D. Watt, Mark J. Truty, Sean P. Cleary, Rory L. Smoot, Julie K. Heimbach, Nguyen H. Tran, Amit Mahipal, Jun Yin, Tyler Zemla, Chen Wang, Zachary Fogarty, Mark Jacobson, Bradley J. Kemp, Sudhakar K. Venkatesh, Geoffrey B. Johnson, David A. Woodrum, Ajit H. Goenka
Jazyk: angličtina
Rok vydání: 2022
Předmět:
Zdroj: Hepatology Communications, Vol 6, Iss 5, Pp 1172-1185 (2022)
Druh dokumentu: article
ISSN: 2471-254X
DOI: 10.1002/hep4.1861
Popis: Prostate‐specific membrane antigen (PSMA) is a validated target for molecular diagnostics and targeted radionuclide therapy. Our purpose was to evaluate PSMA expression in hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), and hepatic adenoma (HCA); investigate the genetic pathways in HCC associated with PSMA expression; and evaluate HCC detection rate with 68Ga‐PSMA‐11 positron emission tomography (PET). In phase 1, PSMA immunohistochemistry (IHC) on HCC (n = 148), CCA (n = 111), and HCA (n = 78) was scored. In a subset (n = 30), messenger RNA (mRNA) data from the Cancer Genome Atlas HCC RNA sequencing were correlated with PSMA expression. In phase 2, 68Ga‐PSMA‐11 PET was prospectively performed in patients with treatment‐naïve HCC on a digital PET scanner using cyclotron‐produced 68Ga. Uptake was graded qualitatively and semi‐quantitatively using standard metrics. On IHC, PSMA expression was significantly higher in HCC compared with CCA and HCA (P
Databáze: Directory of Open Access Journals